That is pretty clear. What matters now is if new management can stabilise the earnings base and then grow it over the next few years.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025